Her2/neu gene amplification in breast carcinoma patients: Our experience with fluorescence in situ hybridization (FISH) technique

Schwab, 1998, Amplification of oncogenes in human cancer cells, Bioessays, 20, 473, 10.1002/(SICI)1521-1878(199806)20:6<473::AID-BIES5>3.0.CO;2-N Slamon, 1987, Human breast cancer: correlation of relapse and survival with amplification of the Her2/neu oncogene, Science, 235, 177, 10.1126/science.3798106 Slamon, 1989, Studies of the Her2/neu proto-oncogene in human breast and ovarian cancer, Science (Wash. DC), 244, 707, 10.1126/science.2470152 Popescu, 1989, Localization of the human erbB-2 gene on normal and rearranged chromosomes17 to bands q12-21.32, Genomics, 4, 362, 10.1016/0888-7543(89)90343-1 DiGiovanna, 1999, Clinical significance of Her2/neu overexpression: part I and II, PPO Updates, 13(9)13(10), 1 Bell, 2002, What can we learn from herceptin trials in metastatic breast cancer?, Oncology, 1, 39, 10.1159/000066200 Marks, 2001, Defining a test for Her2/neu evaluation in breast cancer in the diagnostic setting, Mod Pathol, 14, 677, 10.1038/modpathol.3880372 Pauletti, 2000, Assessment of methods for tissue-based detection of the Her2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry, J Clin Oncol, 18, 3651, 10.1200/JCO.2000.18.21.3651 Penault-Llorca, 1994, Optimization of immunohistochemical detection of erbB2 in human breast cancer: impact of fixation, J Pathol, 173, 65, 10.1002/path.1711730111 Press, 1994, Sensitivity of Her2/neu antibodies in archival tissue samples: potential source of error in the immunohistochemical studies of oncogene expression, Cancer Res, 54, 2771 Jiminez, 2000, Determination of Her2/neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescence in situ hybridization, Mod Pathol, 13, 37, 10.1038/modpathol.3880007 Jacobs, 1999, Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of Her2/neu in breast cancer, J Clin Oncol, 17, 1974, 10.1200/JCO.1999.17.7.1974 Lebeau, 2001, Her2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization, J Clin Oncol, 19, 354, 10.1200/JCO.2001.19.2.354 Onody, 2001, Fluorescence in situ hybridization and immunohistochemical assays for Her2/neu status determination, Arch Pathol Lab Med, 125, 746, 10.5858/2001-125-0746-FISHAI Wolff, 2007, American society of clinical oncology/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 resting in breast cancer, J Clin Oncol, 25, 118, 10.1200/JCO.2006.09.2775 Slamon, 2001, Use of chemotherapy plus a monoclonal antibody against HER2 for metatstatic breast cancer that overexpresses HER2, N Engl J Med, 344, 783, 10.1056/NEJM200103153441101 Baselga, 2006, Adjuvant trastuzumab: a milestone in the treatment of HER-2 positive early breast cancer, Oncologist, 11, 4, 10.1634/theoncologist.11-90001-4 Bilancia, 2007, Lapatinib in breast cancer, Ann Oncol, 18, vi26, 10.1093/annonc/mdm220 Paik, 2002, Real-world performance of HER2 testing-National Surgical adjuvant breast and Bowel Project experience, J Natl Cancer Inst, 94, 852, 10.1093/jnci/94.11.852 Payne, 2008, Predictive markers in breast cancer – the present, Histopathology, 52, 82, 10.1111/j.1365-2559.2007.02897.x Hayat, 2004, Comparison of immunohistochemistry, in situ hybridization, fluorescence in situ hybridization and chromogenic in situ hybridization, 3 Bartlett, 2001, Evaluating HER2 amplification and overexpression in breast cancer, J Pathol, 195, 422, 10.1002/path.971 Gupta, 2003, Comparison of fluorescence and chromogenic in situ hybridization for detection of Her2/neu oncogenes in breast cancer, Am J Clin Pathol, 119, 381, 10.1309/P40P2EAD42PUKDMG Gancberg, 2002, Evaluation of Her2/neu protein expression in breast cancer by immunohistochemistry: an interlaboratory study assessing the reproducibility of Her2/neu testing, Breast Cancer Res Treat, 74, 113, 10.1023/A:1016146130767 Hoang, 2000, Her2/neu gene amplification compared with Her2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma, Am J Clin Pathol, 113, 852, 10.1309/VACP-VLQA-G9DX-VUDF Mass, 2000, The concordance between the clinical trials assays (CTA) and fluorescence in situ hybridization in the herceptin pivotal trails, Proc Am Soc Clin Oncol, 19, 75 Perez, 2002, HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization, Mayo Clinic Proc, 77, 148, 10.1016/S0025-6196(11)62329-X Kobayashi, 2002, Protein overexpression and gen amplification of c-erbB-2 in breast carcinomas: a comparative study of immunohistochemistry and fluorescence in situ hybridization of formalin-fixed, paraffin-embedded tissues, Hum Pathol, 33, 21, 10.1053/hupa.2002.30185 Tsuda, 2001, Detection of Her2/neu (c-erb B-2) DNA amplification in primary breast carcinoma, Cancer, 92, 2965, 10.1002/1097-0142(20011215)92:12<2965::AID-CNCR10156>3.0.CO;2-A Press, 2005, Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials, Clin Cancer Res, 11, 6598, 10.1158/1078-0432.CCR-05-0636 Birner, 2001, Evaluation of the united states food and drug administration-approved scoring and test system of HER-2 protein expression in breast cancer, Clin Cancer Res, 7, 1669 Yaziji, 2004, HER-2 testing in breast cancer using parallel tissue-based methods, J Am Med Assoc, 291, 1972, 10.1001/jama.291.16.1972 Hammock, 2003, Strong Her2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization, Hum Pathol, 34, 1043, 10.1053/S0046-8177(03)00409-X Perez, 2006, HER2 testing by local, central, and reference laboratories in specimens from the north central cancer treatment group N9831 intergroup adjuvant trial, J Clin Oncol, 24, 3032, 10.1200/JCO.2005.03.4744 Tsuda, 2001, Detection of Her2/neu (c-erbB-2) DNA amplification in primary breast carcinoma: interobserver reproducibility and correlation with immunohistochemical HER-2 overexpression, Cancer, 92, 2965, 10.1002/1097-0142(20011215)92:12<2965::AID-CNCR10156>3.0.CO;2-A